Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab PK/PD dose-ranging study in eosinophilic asthma
2010-022510-11Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of mepolizumab in asthma (2 arms), sponsored by GSK. Primary endpoint: Change from baseline in blood eosinophil levels. Started Nov 2010; status: completed.
02
Drugs
mepolizumab
03
Conditions
asthma
Beyond the preview
Go deeper on 2010-022510-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022510-11.